Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

In August 2006, the Interfaith Center on Corporate Responsibility issued a report, "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"...The Business & Human Rights Resource Centre invited the 15 benchmarked companies to respond to the report; the results to date are indicated below. - Abbott Laboratories statement - AstraZeneca response - Boehringer-Ingelheim response - Bristol-Myers Squibb response - Eli Lilly - declined to respond - Gilead Sciences - declined to respond - GlaxoSmithKline response - Hoffman-La Roche - declined to respond - Merck response - Novartis response - Pfizer response - Tibotec (part of Johnson & Johnson) response - sanofi-aventis: We invited sanofi-aventis to respond; no response has been received. - Schering-Plough - declined to respond - Wyeth - press release sent in response to ICCR report

Zeitleiste

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Datum:

4 Mär 2014

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
[PDF] Benchmarking AIDS: 2006 Year End Update

Datum:

30 Nov 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Datum:

13 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Datum:

13 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Datum:

13 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Datum:

12 Sep 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Datum:

6 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Datum:

6 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Reclaman mayor compromiso de las farmacéuticas

Datum:

31 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Datum:

23 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Datum:

23 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Datum:

23 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Datum:

17 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Datum:

17 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Datum:

14 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Datum:

1 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Datum:

1 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Datum:

8 Jan 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Datum:

8 Jan 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English

Vollständige Story anzeigen

Mehr laden Weniger anzeigen

Business & Human Rights
Resource Centre

Kontakt (Impressum)

Business & Human Rights Resource Centre

Kontakt (Impressum)

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Zeitleiste

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.